AGA Family of Websites:
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
September 16, 2020

EoE/EGID and COVID-19 world-wide data collection underway

New registry will help define the impact of COVID-19 on patients with EoE/EGID, and how factors such as age, comorbidities and treatments impact COVID outcomes.
Share on facebook
Share on twitter
Share on linkedin
Share on email

Noam Zevit, MD, Evan Dellon MD, MPH, and Mirna Chehade MD, MPH, are collecting anonymized data on patients with eosinophilic esophagitis (EoE) and eosinophilic gastrointestinal diseases (EGID) who have been infected with COVID-19. The goal of their international registry, SECURE-EOE/EGID, is to get a better understanding of how the virus behaves in these patients in order to provide guidance to caregivers and patients.

Practitioners world-wide are encouraged to report all confirmed cases (including asymptomatic cases identified by through public health screening) and severe cases for whom COVID-19 has not been confirmed because of the lack of available testing (these will be listed as unconfirmed in the questionnaire).

This case report form should be completed after the patient has had COVID-19 for a long enough duration to experience partial or complete recovery, hospitalization or death.

Here’s a reminder on other COVID-19 registries available to GIs.

Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE) registries:

Other registries:

AGA news and updates on
Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.